SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference in New York City on Monday, September 9, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time
- Stifel Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024 at 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: . The webcasts will be available for replay until October 9, 2024 and October 17, 2024, respectively.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download multimedia:
SOURCE Nektar Therapeutics
內克塔治療（納斯達克：NKTR）管理層計劃在即將舉行的投資者大會上進行演講：
- H.C. Wainwright第26屆全球投資大會將於2024年9月9日星期一下午3時（東部時間）/ 下午12時（太平洋時間）在紐約市舉行
- Stifel虛擬免疫與炎症峯會將於2024年9月17日星期二上午12:30（東部時間）/ 上午9:30（太平洋時間）舉行
演示將通過內克塔公司網站的投資者活動部分發布的鏈接進行訪問：。 網絡研討會將分別提供重播，直到2024年10月9日和2024年10月17日。
關於內克塔治療公司
內克塔治療是一家專注於開發針對自身免疫和慢性炎症疾病潛在免疫功能障礙的臨床生物技術公司。內克塔的主導候選藥物是rezpegaldesleukin（NKTR-358），是一種新穎的、首創的調節性t細胞刺激劑，在兩項第20億階段臨床試驗中正在評估，一項用於特應性皮炎，一項用於斑禿症。我們的管線還包括一種臨床前候選藥物NKTR-0165，是一種雙價腫瘤壞死因子受體II激動劑抗體。內克塔與各種合作伙伴共同評估NKTR-255，一種旨在增強免疫系統自然抗癌能力的研究性IL-15受體激動劑，在多項正在進行的臨床試驗中進行評估。內克塔總部位於加利福尼亞州舊金山。欲獲取更多信息，請訪問 ，並關注我們的LinkedIn。
聯繫方式：
對於投資者：
內克塔治療公司的Vivian Wu
628-895-0661
對於媒體人員：
Argot Partners的David Rosen
（212）600-1902
david.rosen@argotpartners.com
查看下載多媒體原始內容：
來源:內克塔治療
